Oral DNA Vaccine Utilizing the Yeast Cell Wall for Dectin-1 Receptor-Mediated Enhancement of Mucosal Immunity
Molecular Pharmaceutics · 03.03.2025 · 22 (3) · 1241-1252
DOI: 10.1021/acs.molpharmaceut.4c00943 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 17.02.2025. Verfasst von Yingqi Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China. Hauptthemen laut MEDLINE: Lectins, C-Type, Cell Wall, Immunity, Mucosal, Vaccines, DNA. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Mucosal vaccines can generate localized mucosal immunity, effectively preventing initial pathogen infection and providing more effective protection. Oral vaccines are an attractive option for inducing mucosal immunity. The yeast cell wall, primarily composed of natural β-1,3-d glucan, can be recognized by the apical membrane receptor, dectin-1, which has a high expression on macrophages and intestinal M cells. In this study, by using vortexing methods to break yeast cell walls into nanometer-sized fragments, which retain the negatively charged β-glucan components on their surface and employing electrostatic adsorption/coextrusion techniques, these fragments were attached onto the surface of PS-DNA NPs, as verified by a scanning electron microscope (SEM), a transmission electron microscope (TEM), and dynamic light scattering (DLS) data. YCW-coated NPs (YNPs) showed greater drug stability compared to NPs in a simulated gastrointestinal environment. In vitro cell evaluation further demonstrated that YNPs were rapidly and efficiently taken up by antigen-presenting cells via receptor dectin-1-mediated endocytosis. In vivo experiments revealed that the oral vaccine elicited high levels of RBD-specific antibodies and triggered extensive cellular immunity in the intestinal mucosa. This study provides new insights into mucosal vaccine research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
ORCID-Profile: Yingqi Liu, Haonan Xing
Förderung
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Liu, Y., Meng, F., Feng, W., Chen, Z., Xing, H., & Zheng, A. (2025). Oral DNA Vaccine Utilizing the Yeast Cell Wall for Dectin-1 Receptor-Mediated Enhancement of Mucosal Immunity. Molecular Pharmaceutics, 22(3), 1241-1252. https://doi.org/10.1021/acs.molpharmaceut.4c00943
Vancouver
Liu Y, Meng F, Feng W, Chen Z, Xing H, Zheng A. Oral DNA Vaccine Utilizing the Yeast Cell Wall for Dectin-1 Receptor-Mediated Enhancement of Mucosal Immunity. Molecular Pharmaceutics. 2025;22(3):1241-1252. doi:10.1021/acs.molpharmaceut.4c00943
BibTeX
@article{Liu2025,
author = {Liu, Yingqi and Meng, Fan and Feng, Wanting and Chen, Zehong and Xing, Haonan and Zheng, Aiping},
title = {Oral DNA Vaccine Utilizing the Yeast Cell Wall for Dectin-1 Receptor-Mediated Enhancement of Mucosal Immunity},
journal = {Molecular Pharmaceutics},
year = {2025},
volume = {22},
number = {3},
pages = {1241--1252},
doi = {10.1021/acs.molpharmaceut.4c00943}
}
EUVIMED